You are here: Home » 2023 » May » Archives for 16th

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Teleperformance SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TLPFY

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the American Depositary Receipts ("ADRs") of Teleperformance SE (OTC: TLPFY) between July 29, 2020 and November 9, 2022, both dates inclusive (the "Class Period"), of the important June 20, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Teleperformance ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Teleperformance class action, go to https://rosenlegal.com/submit–form/?case_id=15278 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Teleperformance's growth in Core Services had been achieved, in part, by requiring its content moderators to engage in inappropriate, traumatic, abusive, and potentially criminal activities; (2) certain Teleperformance social content moderators had been trained with materials which included illicit images of child sexual exploitation; (3) contraband images had been included in Teleperformance Daily Required Reading reports for its content moderation staff; (4) Teleperformance had failed to safeguard child sexual abuse material and had potentially violated strict rules governing the handling of such materials, including rules relating to the National Center for Missing & Exploited Children; (5) Teleperformance had failed to provide adequate training or emotional and psychological support to content moderators exposed to egregious materials, including those exposed to extreme graphic violence and sexual images; (6) Teleperformance had imposed unreasonable time and performance targets that compounded the occupational trauma suffered by its content moderators; (7) Teleperformance had failed to implement or maintain the working conditions represented to investors, including by subjecting the Company's content moderation workers to widespread occupational trauma without psychological support, and with paltry pay, punitive salary deductions, extensive surveillance, and aggressive union–busting tactics; and (8) as a result of the foregoing, Teleperformance was subject to a material, undisclosed risk of legal, regulatory, business, and reputational harm if the truth regarding the Company's content moderation services, treatment of its content moderation workers, and handling of contraband materials was ever publicly revealed. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Teleperformance class action, go to https://rosenlegal.com/submit–form/?case_id=15278 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8840698)

ROSEN, A LEADING LAW FIRM, Encourages Stanley Black & Decker, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SWK

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Stanley Black & Decker, Inc. (NYSE: SWK) between October 28, 2021 and July 28, 2022, both dates inclusive (the "Class Period"), of the important May 23, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Stanley Black & Decker securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Stanley Black & Decker class action, go to https://rosenlegal.com/submit–form/?case_id=13771 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 23, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) rising interest rates, inflation, and trends in returning to work away from home were in fact quickly eroding then heightened demand for Stanley's tools and outdoor products; (2) the heightened, extraordinary demand Stanley had enjoyed as a result of the COVID–19 pandemic in 2021 and 2022 was returning to 2019 pre–pandemic levels; (3) Stanley's operations were already showing signs of slowing demand; (4) as a result of reorganization, share repurchasing, and dividend growth, Stanley lacked the cash to react with agility to changes in demand; (5) as a result of Stanley's inability to react to a sharp decline in demand, the Company's results and metrics, particularly sales volume, were severely negatively impacted; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Stanley Black & Decker class action, go to https://rosenlegal.com/submit–form/?case_id=13771 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8840717)

Nyxoah Présente ses Résultats Financiers et Opérationnels pour le Premier Trimestre 2023

INFORMATIONS RGLEMENTES

Nyxoah Prsente ses Rsultats Financiers et Oprationnels pour le Premier Trimestre 2023

Mont–Saint–Guibert, Belgique "" 16 Mai 2023, 22h05 CET / 16h05 ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ( Nyxoah ou la Socit ) opre dans le secteur des technologies mdicales et se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). Elle annonce aujourd'hui ses rsultats financiers et d'exploitation pour le premier trimestre 2023.

Temps Forts Financiers et Oprationnels

  • Achvement des 115 implants de l'essai pivot DREAM aux tats–Unis, les donnes 12 mois tant attendues au premier trimestre 2024.
  • Lancement de la demande d'autorisation de mise sur le march (PMA) modulaire avec le dpt du premier module.
  • Soumission des donnes 12 mois1 sur les 34 premiers patients DREAM en tant qu'abstract SLEEP 2023, dmontrant un taux de rponse l'IAH de 65 %, un taux de rponse l'ODI de 76 % et une scurit en ligne avec les attentes. L'abstract sera prsent lors d'une session le 6 juin. Ces donnes sont prliminaires et ne permettent pas de conclure au succs final de DREAM.
  • Implantation des premiers patients de l'tude pivot amricaine ACCCESS IDE pour le traitement du collapsus concentrique complet (CCC). La fin des implantations est prvue pour 2024.
  • Embauche de Christoph Eigenmann en tant que Chief Commercial Officer.
  • Leve de fonds de 19 millions d'euros auprs de nouveaux actionnaires et d'actionnaires historiques, notamment ResMed, Cochlear et Robert Taub, Chairman et fondateur de Nyxoah.
  • 40 comptes allemands actifs la fin du trimestre et un chiffre d'affaires trimestriel de 441 000 euros.
  • largissement de l'accs au march europen avec les premires implantations en Autriche.
  • Renforcement de la chane d'approvisionnement avec l'obtention de l'autorisation de l'organisme notifi de l'UE pour l'usine de fabrication en Belgique.

“En 2023, nous nous concentrons aux tats–Unis sur le suivi des patients DREAM, ce qui nous permettra d'atteindre les critres d'valuation primaires. Je suis enthousiasm par les donnes sur les 34 premiers patients et j'ai hte de partager les rsultats complets de l'abstract au congrs SLEEP 2023 le mois prochain. Notre conviction croissante dans les rsultats de DREAM acclre l'investissement dans notre organisation commerciale, en commenant par l'arrive de Christoph en tant que Chief Commercial Officer”, a comment Olivier Taelman, CEO de Nyxoah. “L'embauche de Christoph, ainsi que les 19 millions d'euros levs auprs d'investisseurs cls, nous placent en position de force au moment o nous entamons notre prochaine phase de croissance.”

Rsultats du Premier Trimestre 2023

INFORMATIONS FINANCIRES CONSOLIDES NON AUDITES "" COMPTE DE RESULTATS INTERMEDIAIRES CONSOLIDS POUR LA PERIODE DE TROIS MOIS CLOTURE LE 31 MARS 2023 (en milliers)

Pour la priode de trois mois termine le 31 mars
2023 2022
Chiffre d'affaires 441 660
Cot des biens vendus (175) (289)
Bnfice brut 266 371
Frais de recherche et de dveloppement (6,157) (3,595)
Frais de vente, dpenses administratives et autres frais gnraux (5,551) (4,193)
Autres revenus / (frais) d'exploitation 46 136
Perte d'exploitation de la priode (11,396) (7,281)
Produits financiers 625 1,576
Charges financires (958) (788)
Perte de la priode avant impts (11,729) (6,493)
Impts sur le revenu (182) (208)
Perte de la priode (11,911) (6,701)
Perte attribuable aux actionnaires (11,911) (6,701)
Autres lments du rsultat global
Elments pouvant tre reclassifis en bnfices ou en pertes (nets d'impts)
Diffrences de conversion de devises (28) ( 102)
Perte globale totale de la priode, nette d'impts (11,939) (6,803)
Perte attribuable aux actionnaires (11,939) (6,803)
Perte par action (en ) (0.460) (0.260)
Perte dilue par action (en ) (0.460) (0.260)

INFORMATIONS FINANCIRES CONSOLIDES CONDENSES NON AUDITES – TAT CONSOLID DE LA SITUATION FINANCIRE AU 31 MARS 2023 (en milliers)
En date du
31 mars
2023 		31 dcembre 2022
ACTIFS
Actifs non courants
Immobilisations corporelles 2,721 2,460
Immobilisations incorporelles 42,447 39,972
Droit d'utilisation des actifs 3,669 3,159
Actif d'impts diffrs 50 47
Autres crances long terme 169 173
49,056 45,811
Actifs courants
Stocks 1,249 882
Crances commerciales 1,499 1,463
Autres crances 1,419 1,775
Autres actifs courants 1,663 1,284
Actifs financiers 62,403 76,968
Trsorerie et quivalents de trsorerie 33,664 17,888
101,897 100,260
Total de l'actif 150,953 146,071
CAPITAUX PROPRES ET PASSIFS
Capital et rserves
Capital 4,859 4,440
Prime d'mission 243,488 228,275
Rserve pour paiement fond sur des actions 6,582 5,645
Autres lments du rsultat global 148 176
Rsultats reports (130,051) (118,212)
Total des capitaux propres attribuables aux actionnaires 125,026 120,324
PASSIFS
Passifs non courants
Dettes financires 8,381 8,189
Passifs locatifs 3,112 2,586
Passifs au titre des retraites 25 '
Provisions 74 59
Passif d'impts diffrs ' '
ACTIFS 11,592 10,834
Passifs courants
Dettes financires 390 388
Passifs locatifs 711 719
Dettes commerciales 5,012 4,985
Passif d'impts exigibles 3,619 3,654
Autres dettes 4,603 5,167
14,335 14,913
Total du passif 25,927 25,747
Total des capitaux propres et du passif 150,953 146,071

Revenus

Le chiffre d'affaires s'est lev 441 000 pour le premier trimestre se terminant le 31 mars 2023, contre 660 000 pour le premier trimestre se terminant le 31 mars 2022.

Cot des Marchandises Vendues

Le cot des marchandises vendues tait de 175 000 pour les trois mois se terminant le 31 mars 2023, ce qui reprsente un bnfice brut de 266 000 , soit une marge brute de 60,3 %. titre de comparaison, le cot total des marchandises vendues tait de 289 000 pour le premier trimestre se terminant le 31 mars 2022, soit un bnfice brut de 371 000 , ou une marge brute de 56,2 %.

Frais de Recherche et Dveloppement

Les frais de recherche et dveloppement se sont levs 6,2 millions d'euros pour le trimestre clos le 31 mars 2023, contre 3,6 millions d'euros pour la priode de l'exercice prcdent, sous l'effet d'une acclration des activits cliniques, notamment le dmarrage de l'tude ACCCESS.

Frais Commerciaux, Gnraux et Administratifs

Les frais commerciaux, gnraux et administratifs ont augment pour atteindre 5,6 millions d'euros au premier trimestre 2023, contre 4,2 millions d'euros au premier trimestre 2022. Cela s'explique principalement par l'intensification des efforts commerciaux en Allemagne et sur d'autres marchs europens, ainsi que par des investissements dans l'infrastructure de l'entreprise Nyxoah. La socit prvoit de continuer ajouter des effectifs dans l'ensemble de l'organisation avant le lancement commercial aux tats–Unis.

Perte d'Exploitation

La perte d'exploitation totale pour le premier trimestre 2023 s'est leve 11,4 millions d'euros contre 7,3 millions d'euros au premier trimestre 2022. Cette volution s'explique par l'acclration des dpenses de R&D de la Socit, ainsi que par les activits commerciales et cliniques en cours.

Position de Trsorerie
Au 31 mars 2023, la trsorerie et les actifs financiers s'levaient 96,1 millions d'euros, contre 94,9 millions d'euros au 31 dcembre 2022. La consommation totale de trsorerie a t d'environ 4,9 millions d'euros par mois au cours du premier trimestre 2023.

Rapport du Premier Trimestre 2023
Le rapport financier de Nyxoah pour le troisime 2022, y compris les dtails des rsultats consolids non
audits, sont disponibles sur la page investisseurs du site web de Nyxoah (https://investors.nyxoah.com/financials).

Confrence Tlphonique et Prsentation par Webcast
Nyxoah tiendra une confrence tlphonique ouverte au public aujourd'hui 22h30 CET / 16h30 ET, qui sera galement diffuse sur le web. Pour participer la confrence tlphonique, veuillez accder au lien suivant afin de vous inscrire pour obtenir un numro d'appel : https://edge.media–server.com/mmc/p/imeku8f7

Une sance de questions–rponses suivra la prsentation des rsultats. Pour accder la retransmission
en direct, rendez–vous sur : https://investors.nyxoah.com/events. La retransmission archive sera disponible peu aprs la clture de la confrence.

propos de Nyxoah
Nyxoah opre dans le secteur des technologies mdicales. Elle se concentre sur le dveloppement et la commercialisation de solutions innovantes destines traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le systme Genio , une thrapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reu le marquage CE, centre sur le patient et destine traiter le Syndrome d'Apnes Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associ un risque accru de mortalit et des comorbidits, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits rparatrices et vivre pleinement leur vie.

la suite de la finalisation probante de l'tude BLAST OSA, le systme Genio a reu le marquage europen CE en 2019. Nyxoah a ralis avec succs deux IPO : l'une sur Euronext Bruxelles en septembre 2020 et l'autre sur le NASDAQ en juillet 2021. Grce aux rsultats positifs de l'tude BETTER SLEEP, Nyxoah a reu le marquage CE pour l'extension de ses indications thrapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thrapies concurrentes sont actuellement contre–indiques. En outre, la Socit mne actuellement l'tude pivot IDE DREAM pour la FDA obtenir l'autorisation de mise sur le march.

Pour de plus amples informations, veuillez consulter le site http://www.nyxoah.com/.

Attention "" marquage CE depuis 2019. Dispositif de recherche aux tats–Unis. Limit un usage exprimental aux tats–Unis par la loi fdrale amricaine.

Dclarations Prospectives
Certaines dclarations, croyances et opinions contenues dans le prsent communiqu de presse sont de nature prospective et refltent les attentes actuelles de la socit ou, le cas chant, des administrateurs ou de la direction de la socit concernant le systme Genio , les tudes cliniques prvues et en cours sur le systme Genio , les avantages potentiels du systme Genio ; les objectifs de Nyxoah en ce qui concerne le dveloppement, la voie rglementaire et l'utilisation potentielle du systme Genio ; l'utilit des donnes cliniques pour l'obtention ventuelle de l'approbation du systme Genio par la FDA ; et les rsultats d'exploitation, la situation financire, les liquidits, les performances, les perspectives, la croissance et les stratgies de la socit. De par leur nature, les dclarations prvisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothses et d'autres facteurs qui pourraient faire en sorte que les rsultats ou vnements rels diffrent matriellement de ceux exprims ou sous–entendus dans les dclarations prvisionnelles. Ces risques, incertitudes, hypothses et facteurs pourraient avoir une incidence ngative sur les rsultats et les effets financiers des plans et des vnements dcrits dans le prsent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes noncs dans la section “Facteurs de risque” du rapport annuel de la socit sur le formulaire 20–F pour l'exercice clos le 31 dcembre 2021, dpos auprs de la Securities and Exchange Commission (“SEC”) le 24 mars 2022, et des rapports ultrieurs que la socit dpose auprs de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les vnements, les performances ou les rsultats rels diffrent de manire significative de tout dveloppement anticip. Les dclarations prospectives contenues dans le prsent communiqu de presse concernant des tendances ou des activits passes ne constituent pas des garanties de performances futures et ne doivent pas tre considres comme une dclaration selon laquelle ces tendances ou activits se poursuivront l'avenir. En outre, mme si les rsultats ou dveloppements rels sont conformes aux dclarations prospectives contenues dans le prsent communiqu de presse, ces rsultats ou dveloppements peuvent ne pas tre reprsentatifs des rsultats ou dveloppements des priodes futures. Aucune dclaration ou garantie n'est donne quant l'exactitude ou la justesse de ces dclarations prospectives. En consquence, la socit dcline expressment toute obligation ou tout engagement de publier des mises jour ou des rvisions des dclarations prospectives contenues dans le prsent communiqu de presse la suite d'un changement des attentes ou d'un changement des vnements, conditions, hypothses ou circonstances sur lesquels ces dclarations prospectives sont bases, sauf si la loi ou la rglementation l'exige expressment. Ni la Socit, ni ses conseillers ou reprsentants, ni aucune de ses filiales, ni les dirigeants ou employs de ces personnes ne garantissent que les hypothses sous–jacentes ces dclarations prospectives sont exemptes d'erreurs et n'acceptent aucune responsabilit quant l'exactitude future des dclarations prospectives contenues dans ce communiqu de presse ou quant la survenance effective des dveloppements prvus. Vous ne devriez pas accorder une confiance excessive aux dclarations prospectives, qui ne sont valables qu' la date du prsent communiqu de presse.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 Pour que l'essai soit concluant, il faut qu'au moins 63 % des 115 patients rpondent l'IAH et l'ODI lors du suivi 12 mois.

Pice jointe


GLOBENEWSWIRE (Distribution ID 1000810492)

Nyxoah Reports First Quarter 2023 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports First Quarter 2023 Financial and Operating Results

Mont–Saint–Guibert, Belgium "" May 16, 2023 10:05pm CET / 4:05pm ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2023.

Recent Financial and Operating Highlights

  • Completed all 115 implants in the DREAM U.S. pivotal trial, with 12–month data expected in the first quarter of 2024.
  • Initiated the modular PMA submission with the filing of the first module.
  • Submitted 12–month data1 on the first 34 DREAM patients as a late–breaking abstract to SLEEP 2023 demonstrating a 65% AHI responder rate, a 76% ODI responder rate and safety in–line with expectations. The abstract will be presented in a late–breaking poster session on June 6th. These data are preliminary and not conclusive of final DREAM success.
  • Implanted the first patients in the ACCCESS U.S. IDE pivotal study to treat complete concentric collapse (CCC). Implant completion expected in 2024.
  • Hired Christoph Eigenmann as Chief Commercial Officer.
  • Raised 19 million from new and historical shareholders including ResMed, Cochlear and Robert Taub, Nyxoah's Chairman and Founder.
  • Ended the quarter with 40 active German accounts and quarterly sales of 441 thousand.
  • Expanded European market access with first implants in Austria.
  • Strengthened the supply chain with the Belgium manufacturing facility receiving clearance from the EU notified body.

"In 2023, our focus is in the U.S. on DREAM patient follow up resulting in reaching the primary endpoints. I am excited by the data on the first 34 patients and look forward to sharing the full abstract results at SLEEP 2023 next month. Our increasing conviction in DREAM outcomes is accelerating investment in our commercial organization, starting with the addition of Christoph as Chief Commercial Officer," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "Christoph's hire, along with the 19 million raised from key investors, puts us in a strong position as we embark on our next stage of growth."

First Quarter 2023 Results

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION "" CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2023 (in thousands)

For the three months ended March 31
2023 2022
Revenue 441 660
Cost of goods sold (175) (289)
Gross profit 266 371
Research and Development Expense (6,157) (3,595)
Selling, General and Administrative Expense (5,551) (4,193)
Other income/(expense) 46 136
Operating loss for the period (11,396) (7,281)
Financial income 625 1,576
Financial expense (958) (788)
Loss for the period before taxes (11,729) (6,493)
Income taxes (182) (208)
Loss for the period (11,911) (6,701)
Loss attributable to equity holders (11,911) (6,701)
Other comprehensive loss
Items that may be subsequently reclassified to profit or
loss (net of tax)
Currency translation differences (28) ( 102)
Total comprehensive loss for the year, net of tax (11,939) (6,803)
Loss attributable to equity holders (11,939) (6,803)
Basic Loss Per Share (in EUR) (0.460) (0.260)
Diluted Loss Per Share (in EUR) (0.460) (0.260)

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL INFORMATION "" CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF MARCH 31, 2023 (in thousands)
As at
March 31
2023 		December 31 2022
ASSETS
Non–current assets
Property, plant and equipment 2,721 2,460
Intangible assets 42,447 39,972
Right of use assets 3,669 3,159
Deferred tax asset 50 47
Other long–term receivables 169 173
49,056 45,811
Current assets
Inventory 1,249 882
Trade receivables 1,499 1,463
Other receivables 1,419 1,775
Other current assets 1,663 1,284
Financial assets 62,403 76,968
Cash and cash equivalents 33,664 17,888
101,897 100,260
Total assets 150,953 146,071
EQUITY AND LIABILITIES
Capital and reserves
Capital 4,859 4,440
Share premium 243,488 228,275
Share based payment reserve 6,582 5,645
Other comprehensive income 148 176
Retained loss (130,051) (118,212)
Total equity attributable to shareholders 125,026 120,324
LIABILITIES
Non–current liabilities
Financial debt 8,381 8,189
Lease liability 3,112 2,586
Pension liability 25 '
Provisions 74 59
Deferred tax liability ' '
11,592 10,834
Current liabilities
Financial debt 390 388
Lease liability 711 719
Trade payables 5,012 4,985
Current tax liability 3,619 3,654
Other payables 4,603 5,167
14,335 14,913
Total liabilities 25,927 25,747
Total equity and liabilities 150,953 146,071

Revenue

Revenue was 441,000 for the first quarter ending March 31, 2023, compared to 660,000 for first quarter ending March 31, 2022.

Cost of Goods Sold

Cost of goods sold was 175,000 for the three months ending March 31, 2023, representing a gross profit of 266,000, or gross margin of 60.3%. This compares to total cost of goods sold of 289,000 in the first quarter ending March 31, 2022, for a gross profit of 371,000, or gross margin of 56.2%.

Research and Development Expenses

Research and development expenses were 6.2 million for the three months ending March 31, 2023, versus 3.6 million for the prior year period, driven by an acceleration in clinical activities, notable the start of the ACCCESS study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to 5.6 million for the first quarter of 2023, up from 4.2 million in the first quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah's corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

Operating Loss

Total operating loss for the first quarter 2023 was 11.4 million versus 7.3 million in the first quarter of 2022. This was driven by the acceleration in the Company's R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of March 31, 2023, cash and financial assets totaled 96.1 million, compared to 94.9 million on December 31, 2022. Total cash burn was approximately 4.9 million per month during the first quarter of 2023.

First Quarter 2023 Report
Nyxoah's financial report for the first quarter of 2023, including details of the consolidated results, are available on the investor page of Nyxoah's website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial–in number: https://edge.media–server.com/mmc/p/imeku8f7

A question–and–answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution "" CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20–F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

1 For the trial to be successful, of the 115 patients, at least 63% of patients need to be AHI and ODI responders at the 12–month follow–up.

Attachment


GLOBENEWSWIRE (Distribution ID 1000810492)

Mass General Brigham and Dana-Farber Cancer Institute collaborating with BEEAH Group to advise on a new, patient-centered health care system

Boston, MA, May 16, 2023 (GLOBE NEWSWIRE) — Mass General Brigham and Dana–Farber Cancer Institute are collaborating with BEEAH Group, an organization pioneering sustainability and quality of life solutions in the Middle East, to advise in the development of the Jawaher Boston Medical District, a state–of–the–art health care system designed to deliver world–class, patient–centered care through innovation, technology, and sustainability. Mass General Brigham and Dana–Farber Cancer Institute are strategic partners, serving in an advisory capacity, on the project in Sharjah, United Arab Emirates, which includes a multi–specialty flagship hospital for integrated, cutting–edge care.

The collaboration combines the depth and breadth of clinical expertise and innovation from Mass General Brigham and Dana–Farber Cancer Institute, with BEEAH's vision to create a sustainable, advanced, patient–centered health system designed to deliver care to patients within "" and beyond "" hospital walls. BEEAH Group was founded in 2007 to tackle sustainability challenges in Sharjah and improve quality of life.

Focused on serving the unique needs of the people of Sharjah and the region, the Jawaher Boston Medical District will offer patients access to the latest clinical expertise across a wide variety of integrated clinical specialties, including lifestyle medicine and prevention, oncology, women's health, pediatrics, cardiovascular, neurosciences, behavioral health, and rehabilitation medicine. In addition to medical and research expertise, Mass General Brigham and Dana–Farber Cancer Institute will also collaborate with BEEAH Group to advise on best practices in workforce training, development, and public education to the community, with attention to developing local talent.

Mass General Brigham and Dana–Farber Cancer Institute are advising BEEAH Group in their development of multiple facilities, comprising the flagship hospital and ambulatory clinics across Sharjah, with integrated, innovative, and digital solutions, including app–based care and hospital–at–home.

"Mass General Brigham has a deep history of global collaboration aimed at serving and improving the lives of patients around the world," said Raymond W. Liu, MD, Vice President, Mass General Brigham Global Advisory. "In collaborating with BEEAH, we hope to contribute our decades of expertise to their development of a unique, innovative vision for a health system that builds on medicine's leading edge, with an eye to the future."

"Dana–Farber, a world leader in cancer treatment and research, is committed to advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases locally and globally," said Adam Reich, Vice President of Business Initiatives at Dana–Farber Cancer Institute. "We are pleased to work with BEEAH and extend our expertise to this collaboration as part of our mission to enhance access to expert cancer care and reduce the burden of cancer worldwide."

By leveraging its expertise in quality–of–life solutions in Sharjah and the Middle East, BEEAH will create a new destination for the health, wellness and quality of life for the people of Sharjah and the region focused on patient outcomes and experience gleaned from a robust academic ecosystem pioneered, developed and refined over two centuries by Mass General Brigham and Dana–Farber Cancer Institute clinicians.

By pooling their combined medical, research and sustainability expertise, Mass General Brigham, Dana–Farber Cancer Institute and BEEAH will develop innovative technologies, diagnostics, delivery models and patient care, ultimately fostering research, directly benefitting patients globally and providing valuable cross–institutional learnings in the United States. The outcome will enable BEEAH to create a comprehensive patient–centered health care system for the people of Sharjah and the UAE, integrating healthcare solutions into homes, schools, workplaces, and communities to help all patients and their families live healthier lives.

"By partnering with Mass General Brigham and Dana–Farber Cancer Institute, BEEAH Group is entering the healthcare industry and adding a new dimension to our purpose of pioneering a sustainable quality of life for the people of Sharjah, the UAE, and beyond," said Khaled Al Huraimel, Group CEO of BEEAH Group. "Drawing from the expertise of our partners in Boston, we look forward to creating not just an integrated health network, but a future–ready healthcare ecosystem. The Jawaher Boston Medical District will provide patients in Sharjah access to world–class healthcare closer to home, while also serving as a hub for the development of cutting–edge treatments and medical advancement."

The project draws from Mass General Brigham and Dana–Farber Cancer Institute's medical and research expertise, as well as BEEAH Group's experience collaborating and innovating with international partners to create facilities that are sustainable, digitally–enabled and centered around the comfort and convenience of occupants.

Following a meeting of representatives from Mass General Brigham, Dana–Farber Cancer Institute and BEEAH Group, Sheikha Jawaher Al Qasimi, Wife of the Ruler of Sharjah and Chairperson of BEEAH Group, and Meghan Gregonis, United States General Consul in Dubai, the Jawaher Boston Medical District in Sharjah was approved to move forward.

###

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long–term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation's leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit www.massgeneralbrigham.org.

About Dana–Farber Cancer Institute
Dana–Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. Dana–Farber's mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana–Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

We provide the latest treatments in cancer for adults through Dana–Farber Brigham Cancer Center and for children through Dana–Farber is the only hospital with a top 4 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana–Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials.

For more information, please visit www.dana–farber.org.

About BEEAH Group
BEEAH Group is the region's leading sustainability and digitalisation expert, renowned for ground–breaking environmental innovations and smart solutions for future–ready cities. Recognising sustainability and technology as the pillars of a modern economy, BEEAH Group has invested in a comprehensive, full–circle strategy for the future. BEEAH Group operates in the industries of waste management, renewable energy, technology, consulting, education, transport, real estate and healthcare. Raising the bar for the quality of life in the region, BEEAH Group businesses continue to set industry benchmarks in sustainable, smart solutions and help countries across the region create and execute their roadmap for a socially responsible future. The Group currently operates in the UAE, Egypt and KSA."For more information, please visit www.beeahgroup.com and connect on LinkedIn, Instagram, Facebook and Twitter @beeahgroup


GLOBENEWSWIRE (Distribution ID 8840712)

DIS INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages The Walt Disney Company Investors to Secure Counsel Before Important Deadline in Securities Class Action – DIS

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of The Walt Disney Company (NYSE: DIS) between December 10, 2020 and November 8, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023.

SO WHAT: If you purchased Disney securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Disney class action, go to https://rosenlegal.com/submit–form/?case_id=16164 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The Complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Disney+ was suffering decelerating subscriber growth, losses, and cost overruns; (2) the true costs incurred in connection with Disney+ had been concealed by Disney executives by debuting certain content intended for Disney+ initially on Disney's legacy distribution channels and then making the shows available on Disney thereafter to improperly shift costs out of the Disney+ segment; (3) Disney Media and Entertainment Distribution (“DMED”) had made platform distribution decisions based not on consumer preference, consumer behavior, or the desire to maximize the size of the audience for the content as represented, but based on the desire to hide the full costs of building Disney+ 's content library; (4) Disney was not on track to achieve even the reduced 2024 Disney paid global subscriber and profitability targets, such targets were not achievable, and such estimates lacked a reasonable basis; and (5) defendants had materially misrepresented the actual performance of Disney+, the sustainability of Disney+'s historical growth trends, the profitability of Disney+, and the likelihood that Disney could achieve its 2024 Disney+ subscriber and profitability targets. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Disney class action, go to https://rosenlegal.com/submit–form/?case_id=16164 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8840685)

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sprit AeroSystems Holdings Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPR

NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) between April 8, 2020 and April 13, 2023, both dates inclusive (the "Class Period"), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Spirit AeroSystems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit–form/?case_id=15844 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Spirit lacked effective production quality controls; (2) that, as a result, Spirit incorrectly installed fittings designed to join the aft fuselage to the vertical tail for some Boeing 737 Max airplanes that Spirit sent to Boeing; (3) that, as a result, Spirit would have to develop an inspection and repair procedure for the affected fuselages; (4) that the foregoing would negatively impact Spirit's financial results; and (5) that as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Spirit AeroSystems class action, go to https://rosenlegal.com/submit–form/?case_id=15844 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8840669)

Zoom Partners with Anthropic to Expand Federated Approach to AI

SAN JOSE, Calif., May 16, 2023 (GLOBE NEWSWIRE) — Today, Zoom announced a strategic partnership with and investment in Anthropic, an AI safety and research company working to build reliable, interpretable, and steerable AI systems. The collaboration with Anthropic will further bolster Zoom's federated approach to AI by allowing Anthropic's AI assistant, Claude, to be integrated with Zoom's platform (which includes Team Chat, Meetings, Phone, Whiteboard, Zoom IQ), starting with Zoom Contact Center.

"Anthropic's Constitutional AI model is primed to provide safe and responsible integrations for our next–generation innovations, beginning with the Zoom Contact Center portfolio. With Claude guiding agents toward trustworthy resolutions and powering self–service for end–users, companies will be able to take customer relationships to another level," said Smita Hashim, chief product officer for Zoom. "Partnering with Anthropic also furthers our commitment to providing customers with our federated approach to AI, optimized to deliver outstanding customer experience outcomes. Additionally, with our investment, we are advancing leading–edge companies like Anthropic and helping to drive innovation in the Zoom ecosystem and beyond."

"Partnering with a leading collaboration platform like Zoom allows us to put robust, steerable AI into the hands of more people and unlock its potential to help streamline everyday processes," said Dario Amodei, CEO and co–founder of Anthropic. "We look forward to working together to showcase Anthropic's capabilities and our joint commitment to enhancing productivity through intelligent solutions."

Zoom's federated approach to AI leverages its own proprietary AI models, along with those from leading AI companies "" such as Anthropic "" and select customers' models. With this flexibility to incorporate multiple types of models, Zoom can provide the most value for its customers' diverse needs. Zoom will be able to customize these models to perform better for a customer, based on their specific business needs.

As the next step in evolving the Zoom Contact Center portfolio, (Zoom Virtual Agent, Zoom Contact Center, Zoom Workforce Management), Zoom plans to incorporate Anthropic AI throughout its suite, improving end–user outcomes and enabling superior agent experiences. The Zoom Contact Center suite of solutions elevates the quality of customer experiences through better self–service and the ability to accurately understand customer intent. It intelligently guides customers to the best resolution, surfaces actionable insights that managers can use to coach their agents, and improves productivity by providing a unified communications and contact center experience. In the near future, Zoom will also use AI to provide the right resources to agents, so customers receive exceptional service experiences regardless of their reason for calling.

Announced today, Zoom Ventures has made an investment in Anthropic, strengthening the relationship between both companies. Anthropic's research and development aims to create steerable, trustworthy, and responsible large–scale AI systems. Zoom did not disclose the amount of the investment.

About Zoom
Zoom is an all–in–one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Zoom Public Relations
Lacretia Taylor
press@zoom.us


GLOBENEWSWIRE (Distribution ID 8840480)

Will COP28 Catch the Next Green Wave … Or Will It Wipe Out?

UAE’s role as COP28 host will be judged on results. Will COP deliver an operational and meaningful loss and damage fund? Will it produce a global stocktake that invigorates international action? How will discussions on a new global finance goal shape up? And will Sultan Al Jaber’s overtures towards the private sector turn the steady trickle of pledges into a giant wave of action? Credit: Isaiah Esipisu/IPS

By Felix Dodds and Chris Spence
NEW YORK, May 16 2023 – Perhaps one of the least well known among Dubai’s many attractions is surfing. Locals and visitors enjoy the sport at Sunset Beach and elsewhere, especially in winter. There is even an artificial wave pool where surfers can hone their skills. To some, the pool is just another example of the host country’s entrepreneurial outlook.

With COP28 on the horizon, the host government of the United Arab Emirates is once again promoting the virtues of business. In a recent interview with the Guardian media outlet, COP28 president-designate Sultan Al Jaber said the world needs a “business mindset” to tackle the climate crisis. What’s more, he laid out plans to use the COP to promote private sector goals as well as those for governments.

Will this focus on business signal a genuine new green wave, or will it wipe out? This article assesses the state of play and the host’s approach as we head into the official preparatory meetings taking place in Bonn, Germany, in June.

 

What was achieved at COP27?

To understand the situation, we need first to look at what happened at COP27. This is important not just in terms of the current landscape, but because the COP27 hosts, Egypt, technically continue to hold the presidency until COP28 officially starts on November 30th.

The main source of disappointment at COP27 was the absence of ambition on mitigation. There was a noteworthy lack of new and ambitious Nationally Determined Contributions (NDCs) from governments. What this means is that the critical needle has not shifted when it comes to keeping global warming to less than 1.5 Celsius, or even under 2C

While all incoming presidencies are incredibly active in the months leading up to the event they will host, the outgoing presidency has a role to play, too, and the quality of the relationship between the two governments is important.

For many UN insiders, COP27 exceeded expectations. Admittedly, expectations were not high, particularly since COP27 was viewed by many as an “in-between” COP rather than one with critical milestones of the sort that occur every few years. While all COPs matter, most insiders will tell you not all are equal in importance.

The COP in Sharm El-Sheikh had a menu of issues it was dealing with, but it was not one where, say, a new global agreement was expected (such as COP21 in Paris), or a global stock take was due (as will happen at COP28 later this year). There had been calls for governments to strengthen their Nationally Determined Contributions (pledges and commitments) at COP27, but few did.

The major achievement at COP27—and the reason the meeting exceeded expectations—was an agreement to establish a loss and damage fund to support vulnerable countries. Few anticipated such a positive outcome even a few weeks prior to the meeting.

Although the agreement on loss and damage did not include acceptance of historical responsibility, it was viewed as a big win for the Egyptian Presidency, small islands and other vulnerable states, as well as the Group of 77 developing countries, which in 2022 was under the presidency of Pakistan.

Under the terms of the agreement at COP27, the loss and damage fund will need to be operationalized at COP28 and a transitional committee is already working on this. In the world of multilateral diplomacy, this is an ambitious timeframe.

There was another positive development on a modest scale at COP27 on the Global Goal on Adaptation. Delegates agreed to “initiate the development of a framework” to be available for adoption in 2024. Meanwhile, on agriculture a new four-year process was agreed to carry on the work started under the Koronivia Joint Work on Agriculture. There is a sense now that agriculture and food security are gaining the attention they deserve in climate negotiations.

Outside the formal negotiations, many projects and alliances were advanced, including plans to accelerate the decarbonization of five major sectors: power, road transport, steel, hydrogen, and agriculture. Noteworthy initiatives included the launch of the Global Renewables Alliance, which brings together leaders from the wind, solar, hydropower, green hydrogen, long duration energy storage, and geothermal sectors.

 

Research released just before COP27 showed that the Global North is still not delivering on its commitment to provide $100 billion a year to the Global South. One silver lining to this dark cloud is that this goal may finally be reached in time for COP28. Still, that is three years too late. Credit: Shutterstock

Research released just before COP27 showed that the Global North is still not delivering on its commitment to provide $100 billion a year to the Global South. One silver lining to this dark cloud is that this goal may finally be reached in time for COP28. Still, that is three years too late. Credit: Shutterstock

 

What was not achieved at COP27?

The main source of disappointment at COP27 was the absence of ambition on mitigation. There was a noteworthy lack of new and ambitious Nationally Determined Contributions (NDCs) from governments.

What this means is that the critical needle has not shifted when it comes to keeping global warming to less than 1.5 Celsius, or even under 2C. According to the Climate Action Tracker, our long-term scenarios are still well above 2C under most scenarios, and as high as 3.4C under their most pessimistic estimate. This means things have not really improved since COP26.

What’s more, research released just before COP27 showed that the Global North is still not delivering on its commitment to provide $100 billion a year to the Global South. One silver lining to this dark cloud is that this goal may finally be reached in time for COP28. Still, that is three years too late.

Meanwhile, COP27 did less to clarify new rules for the global carbon market than many were hoping to see. While COP26 in Glasgow had provided more details about Paris Agreement Article 6 (which sets out a framework for international cooperation and carbon markets), more granular guidance is still needed.

Some fear that without more details on accountability and measurement, for instance in terms of carbon offsets, we could end up with a “wild west” when it comes to the markets.

There was also little progress in negotiations aimed at encouraging the phasedown of unabated coal power and phase out of inefficient fossil fuel subsidies. On the private sector side, while many companies have made net-zero targets, research suggests many do not have robust plans to deliver this, and there is uncertainty over how the private sector will use carbon offsets. Without greater clarity, this hyped-up “wave” of pledges from businesses around COP26 and before may end up a damp squib.

 

Looking to the Bonn climate conference

The political backdrop to the UN Bonn climate conference in June is complex. On the downside, governments are still emerging from the COVID pandemic and many are still focused on, and feeling the impact of, the war in Ukraine.

On the positive side, the cost of solar and wind continues to fall and European countries are moving more quickly because they want to be independent of Russian fossil fuels. Although others are taking advantage of Europe’s reduced demand to increase purchases of Russia’s fossil fuels at reduced prices, the growing focus on renewable energy in many countries should be seen as a positive overall in terms of climate mitigation.

With some major milestones coming up at COP28 later this year, the Bonn conference in June will give us some signals of how close we will be to delivering success in December.

 

Global Stocktake: UN climate negotiators are expected to take stock of progress on the Paris Agreement every five years. COP28 marks the culmination of the first “stocktake” and will be expected to shape and catalyze future action.

The stocktake has three phases. In the first phase, which started at COP26, information is collected and prepared from various sources to help assess progress. Phase 2, which started last year, includes in-person “technical dialogues” focused on mitigation, adaptation, and implementation. These will conclude in Bonn this June.

Finally, the stocktake will end at COP28 with a presentation of findings and discussions on how to respond. The Bonn meeting will therefore present an opportunity to take the pulse of these discussions. How robust have the technical dialogues been? Is there a surge of support from governments to make COP28 a major milestone for climate action? Bonn should provide clues about this.

 

Loss and Damage Fund: The transitional committee has been established and had its first meeting in Luxor, Egypt, in April. It will meet again in Bonn. Its role is to make recommendations on how to operationalize both the new funding arrangements and the fund at COP28. How are these discussions proceeding? Bonn should give some indications on progress, as well as potential areas of discord and disagreement.

 

Global Goal on Adaptation: With significant change already “baked in” to our climate system, effective adaptation will be critical. The Global Goal on Adaptation was agreed under the Paris Agreement and recognizes the need to build adaptive capacity, strengthen resilience and limit vulnerability.

Adaptation will be addressed in Bonn under both the Subsidiary Body for Implementation (SBI) and the Subsidiary Body for Scientific and Technological Advice (SBSTA). It also links to the work of the Sendai Framework for Disaster Risk Reduction 2015-2030, a related UN initiative which is having its “mid-term review” at UN Headquarters in New York from 18-19 May.

 

New Collective Quantified Goal on Climate Finance: The goal of providing $100 billion in support annually for the Global South by 2020 was originally set in 2009. Now it is up for review. Since that earlier goal was viewed as a “floor” rather than a ceiling, many are expecting more ambitious targets in future.

A new goal is supposed to be set before 2025, meaning COP29 in 2024 should mark the moment when a new number (or set of numbers) is agreed. Again, Bonn will mark a moment to assess how those conversations are going, especially given the wide differences in the type of dollar figures being bandied about by the Global North and Global South (many of whom are calling for trillions). Those following this topic can look to the 6th Technical Expert Dialogue, which is taking place in Bonn, to get a sense of progress.

 

Carbon Markets: As mentioned above, in spite of progress many are still hoping for more granular details on the carbon markets. This will be vital to curtail greenwashing with offsets.

 

Coalitions of the Willing: Sultan Al Jaber, the COP28 president-designate, recently highlighted the private sector’s role in combating climate change. In fact, all stakeholders will need to be fully engaged if we are to have any chance of staying withing 1.5C of warming. Voluntary coalitions of governments, the private sector and many others will be vital, especially when it comes to advancing issues where all 190+ governments that are party to the UN climate treaty and Paris Agreement are not yet ready or willing to agree.

Such voluntary initiatives offer considerable scope for those who want to move ahead. In turn, this has the potential to set precedents and entrench ideas that might be taken up by all governments in future formal UN negotiations. An example of this is the methane pledge, which involved some 50 countries reporting on progress at COP27. More should be looked for at COP28. Likewise, the Glasgow Financial Alliance for Net Zero, which has reportedly had some teething problems since its launch in 2021, will hopefully use COP28 as a moment to showcase progress and put its early difficulties behind it.

 

Will COP28 Launch a New Green Wave?

Eyebrows were raised when the United Arab Emirates was first named as host of COP28. Why, people asked, would a climate COP be held in an OPEC state? Furthermore, many wondered publicly whether Sultan Al Jaber, who is likely to preside over the meeting, should do so given his role as chief executive of UAE’s national oil company? Does this represent a conflict of interest?

These are fair questions that will only be fully answered by the COP and what it achieves. However, it is worth noting that the prospects of a fossil fuel-producing country hosting COP28 were always quite high.

As UN insiders know, the climate COPs are typically hosted on a rotating basis in each of the UN’s five “regional groups.” This time around, it was Asia-Pacific’s turn.

Many countries in this region, including more than a dozen small island nations, probably do not have the internal capacity to host an event of this magnitude. Of those that do, many—from Saudi Arabia to India, Indonesia to China, Iran to Australia—are fossil-fuel producers.

Furthermore, while Sultan Al Jaber has a history in the fossil-fuel industry, he has also been prominent in the UAE’s work on renewable energy and is the founding CEO and current Chair of Masdar, a UAE-owned renewable energy company. Depicting him simply as a fossil fuel “dinosaur” does not do justice to a more nuanced and complicated situation.

Ultimately, UAE’s role as COP28 host will be judged on results. Will COP deliver an operational and meaningful loss and damage fund? Will it produce a global stocktake that invigorates international action? How will discussions on a new global finance goal shape up? And will Sultan Al Jaber’s overtures towards the private sector turn the steady trickle of pledges into a giant wave of action?

Finally, will other stakeholders, like non-governmental organizations, be embraced and welcomed? We should also note the significance of appointing Razan Al Mubarak as UN Climate Change High-Level Champion for the COP28 Presidency, given she is also IUCN President and a former head of Abu Dhabi’s Environment Agency.

One early indicator in Bonn will be an expected update on COP28 logistics. This is likely to include more details on the “Blue Zone” (where negotiations are held and many stakeholders usually have pavilions and stalls). Will the Blue Zone offer easy access to all stakeholders? And how will the “Green Zone,” which at past COPs has been open to the public, operate?

Only time will tell if COP28 marks the start of a new green wave or ends in an unfortunate wipe out.

 

Professor Felix Dodds is Vice President of Multilateral Affairs, Rob and Melani Walton Sustainable Solutions Service (RMWSSS) at Arizona State University. He is also Adjunct Professor and Senior Fellow at the Global Research Institute, University of North Carolina, and Associate Fellow at the Tellus Institute, Boston.

Chris Spence is a consultant and advisor to a range of international organizations on climate change and sustainable development, as well as an award-winning writer. Spence and Dodds recently co-edited Heroes of Environmental Diplomacy: Profiles in Courage (Routledge, 2022).

Excerpt:

The hosts of COP28 are betting big on business and a private sector “mindset” to deliver a successful event. Are they right? Professor Felix Dodds and Chris Spence review the current state-of-play

Why Quality Seeds Are among the Most Valuable Currency in Climate Finance for Africa

Joy of Marketing – Ethiopia. Credit: International Seed Federation

By Michael Keller
VAUD, Switzerland, May 16 2023 – At long last, momentum is growing for an overdue rethink of climate finance and development assistance to support countries on the frontlines of the climate crisis.

But while investment, aid and compensation are all much needed, another form of currency is equally valuable for climate-vulnerable countries that are also highly dependent on small-scale agriculture: quality seeds.

The latest generation of seeds offers varieties adapted to specific climatic circumstances to provide more reliable food production, as well as improved incomes and livelihoods for farmers, having boosted productivity by 20 per cent for nine key crops in the European Union over 15 years.

Yet improved varieties of many of the world’s staple cereals, vegetables and pulses are too often inaccessible for farmers in Africa, despite having some of the greatest exposure to climate extremes.

For instance, in East Africa, certified quality seed potatoes – which produce higher yields and greater resilience to climatic changes, pests, and diseases – account for just one per cent of all those planted by farmers.

By leveraging the advances and resources of the commercial seed sector – supported and scaled by public and NGO partners – the global community can ensure African farmers receive the tangible, long-term support they need to cope with the impacts of climate change.

Michael Keller

To begin with, delivering the best varieties in combination with training in good agricultural practices for farmers can boost their yields and therefore incomes, allowing them to thrive despite the rising impact of climate change.

For example, non-profit Fair Planet coached more than 2,300 lead farmers in 65 Ethiopian villages and trained their regional extension agents in improved farming practices. With this training, farmers were able to quickly adopt and maximize their crop yields using locally tested and improved varieties of vegetables.

In total, some 75,000 smallholder farmers in the project’s regions subsequently tripled their vegetable production at a time when the Horn of Africa faced pressing food security challenges. As a result of an historic, ongoing drought, an estimated 22 million people are currently facing acute food insecurity across Ethiopia, Kenya, and Somalia.

According to an external evaluation, more than 95 per cent of households involved in Fair Planet’s work in Ethiopia – or roughly 485,000 people – benefitted from improved nutrition after the increased yields raised household incomes in just one production season by more than 25 per cent. This extra income provided farmers with a greater buffer against climate shocks, and more money to spend on health services and education for their families.

Opening up access to improved varieties of staple crops plays an important role in safeguarding food and nutrition security in the face of climate change, which could reduce levels of protein, iron and zinc in cereals by up to 10 per cent.

This is why the International Seed Federation (ISF), together with Fair Planet, is embarking on a five-year project to increase farmer choice of and access to quality seeds in Rwanda.

The aim is to benefit 84,000 Rwandan farmers by offering increased access to improved, high-quality vegetable, pulses, cereal, and potato varieties alongside downstream value chain projects training to support higher yields and incomes, and climate adaptation.

The final piece of the puzzle is to establish the policies and regulations needed to develop resilient and sustainable seed systems that benefit farmers. This requires policymakers to build an efficient and effective regulatory framework that provides reassurance to farmers that they are receiving the highest quality seed year after year, while also providing the long-term certainty likely to incentivize additional private sector investment.

Quality seeds are clearly the bedrock upon which productive and resilient farming systems are built, yet these technologies up to now remain out of reach for many of Africa’s farmers – one of the many significant challenges they face today.

By investing and collaborating to build resilient seed systems, the private sector can share more broadly the fruits of progress in global crop science through partnerships that ensure farmers receive seeds that are not only fit for purpose but fit for the future.

Improved seeds can then pay dividends by unlocking better productivity, incomes, and climate resilience for those on the frontlines who have for too long been underserved.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Excerpt:

Michael Keller is Secretary General of International Seed Federation